LEGN · Legend Biotech Corporation
$19.19
-3.62% last session
End-of-day data · close of 2026-09-10
Market cap
$4B
Enterprise value
$3B
Trailing P/E
—
Forward P/E
17.8
Dividend yield
—
Beta
0.40
Avg volume
2M
Employees
3K
Daily Change %
-3.62%
5 Days Change
-7.48%
10 Days Change
-4.19%
30 Days Change
-8.80%
60 Days Change
-26.48%
Month to Day Change
-5.77%
Year to Day Change
-8.42%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — LEGN
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-09-04
Latest call per bank · past 12 months
Morgan Stanley
Overweight$49.00
+155.3% vs priceRBC Capital
Outperform$58.00
+202.2% vs priceBarclays
Overweight$78.00
+306.5% vs priceUBS
Neutral$28.00
+45.9% vs priceJP Morgan
Overweight$76.00
+296.0% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-04 | HC Wainwright & Co. | Reiterates | Buy | $65.00 |
| 2026-08-12 | Morgan Stanley | Maintains | Overweight | $48.00 → $49.00 |
| 2026-08-12 | TD Cowen | Maintains | Hold | $29.00 → $24.00 |
| 2026-08-12 | Oppenheimer | Downgrade | Outperform → Perform | $75.00 → $40.00 |
| 2026-08-12 | RBC Capital | Maintains | Outperform | $59.00 → $58.00 |
| 2026-08-12 | Barclays | Maintains | Overweight | $80.00 → $78.00 |
| 2026-07-28 | HC Wainwright & Co. | Reiterates | Buy | $65.00 |
| 2026-07-27 | RBC Capital | Maintains | Outperform | $63.00 → $59.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-10
- RSI (14): RSI is 38 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 13.4% below the 50-day MA ($22.15).
- Price vs 200-day MA: Trading 16.6% below the 200-day MA ($23.01).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is negative (-0.03) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($16.65) and high ($36.28).
LEGN Price Chart
Loading chart for LEGN…
Fundamentals
About Legend Biotech Corporation
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$130B 14.9% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$82B 5.0% YTD
ARGX
argenx SE
$62B 19.2% YTD
MRNA
Moderna, Inc.
$55B 359.9% YTD
RVMD
Revolution Medicines, Inc.
$44B 160.7% YTD
ONC
BeOne Medicines Ltd.
$39B 15.5% YTD
RPRX
Royalty Pharma plc
$34B 59.0% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$33B -35.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.